"By using these biomarkers, we can test new candidates for neuroprotection and vision restoration in a shorter time frame, and that should help us to accelerate investigations toward finding new treatments for glaucoma," Dr. Goldberg said.
The new biomarkers include new imaging modalities being developed in the laboratory of Alfredo Dubra, PhD, associate professor of ophthalmology, Stanford University School of Medicine.
"Dr. Dubra and colleagues are creating new adaptive optics-based imaging modalities that are providing very high-resolution measurements of RGCs, their axons, and even the subcellular elements inside the axons that we think will give us insight on the mitochondrial health of the cells," Dr. Goldberg said.
"With this noninvasive modality, we will be able to determine with confidence whether investigational agents are having biologic effects in early phase clinical testing," Dr. Goldberg said.
Jeffrey L. Goldberg, MD, PhD
E: [email protected]
This article was adapted from Dr. Goldberg's presentation during Glaucoma Subspecialty Day at the 2017 meeting of the American Academy of Ophthalmology. Dr. Goldberg has no financial interests in the products discussed.